The present invention is in the field of graft versus host disease treatment and relates to a composition for use in the treatment of acute Graft-versus-Host Disease (GVHD) in a transplantation recipient after allogenic transplantation with at least one solid organ and/or hematopoietic cells (HC) from a human leucocyte antigen (HLA)-mismatched transplantation donor.